Exelixis Inc – EXEL

April 1, 2018 – June 30, 2018 all-day

Exelixis Inc, EXEL, has Phase 3 data due 1H 2018.

Drug: IMblaze370 – cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer

finviz dynamic chart for  EXEL

Author: ZitroStocks

Welcome to ZitroStocks, hope you enjoy your visit. You are welcome to ask questions and participate in discussions.

One thought on “Exelixis Inc – EXEL”

  1. Tough to play this catalyst, as phase 3 data is in the first half of 2018. Will update if more define date is release.
    Buy Zone: $20.00 to $22.00
    Profit Zone: $30.00 or higher
    Stop Zone: $19.00 or below

Leave a Reply

Your email address will not be published. Required fields are marked *